




The RENCAREX[®] alliance in the US
WILEX & Prometheus – strong partners in oncology
2 May 2011

- **WILEX has granted exclusive commercialization rights for RENCAREX® to Prometheus Laboratories Inc. (Prometheus) in the US**

- **WILEX will receive from Prometheus**
 - \$39 million in cash:
 - \$19 million in cash upon signing **AND**
 - either \$20 million in cash after twelve months or European commercial rights to an undisclosed product **AND**
 - Milestones and co-funding for the ongoing development of RENCAREX® **AND**
 - Royalties on US net sales of RENCAREX®
 - RCC and potential development in further indications

- **Deal valued at > \$145 million in cash for upfront, milestone payments and reimbursed costs plus royalties for US only**

**Prometheus –
preferred US partner for RENCAREX®**




(Rx = medical prescription, therapeutics / Dx = diagnosis)



- **Headquarters: San Diego, CA**
- **CLIA-certified laboratory in San Diego**
- **483 employees, including 178 in Gastroenterology and Oncology commercial teams**

Significant Growth in Therapeutics / Diagnostics



- **Total revenues in 2010: USD 519.0m (2006: USD187.4m)**
- **Net sales of therapeutics in 2010: USD 434.7m (2006: USD 119.m)**
- **Net income in 2010: USD 48.2m (2006: USD 32.2m)**

(Rx = medical prescription, therapeutics / Dx = diagnosis)

Prometheus marketed product portfolio

Therapeutics

Proven Ability to Reinvigorate and Grow Therapeutic Products

- ENTOCORT® EC
- LOTRONEX®

Initial Therapeutic with Dx Potential

- PROLEUKIN®

Diagnostics

Proprietary, High-Margin Diagnostics

- Inflammatory Bowel Disease – IBD Serology 7 Test
- Crohn's Prognostic Test
- Thiopurine Management Tests
- Celiac Tests

CEER™ Oncology Dx

- Proprietary technology that identifies protein pathway expression, activation and modification
- Highly sensitive and specific test platform

Prometheus: Differentiated Partner for Rx and Dx

(*Rx = medical prescription, therapeutics / Dx = diagnosis)



2005

- Deep expertise in therapeutics and diagnostics



2007

- Differentiated physician calls



2009

- Scalable commercial platforms in GI and Oncology position Prometheus as 'best-in-class' partner

CEER Oncology Dx Agreement

2010

- Innovative CEER™ platform advances the deployment of personalized medicine



CEER Oncology Dx Collaboration, Mutational Analysis Agreement

2010



CEER Oncology Dx Agreement

2010



PROMETHEUS®
Therapeutics & Diagnostics

WILEX' business model and pipeline complement Prometheus' Proleukin in the US

→ RENCAREX®

→ The combination of Proleukin® and RENCAREX® prolonged the survival in a Phase II trial in metastatic renal cancer patients

→ REDECTANE®

→ High expression of the CAIX antigen is associated with improved response in patients with renal cancer undergoing Interleukin-2 therapy

→ CAIX ELISA and IHC biomarker tests

→ Stratifying patients for CAIX related therapies

→ Intellectual Property

→ WILEX owns patent applications protecting the combination treatment of RENCAREX® and Interleukin-2 for the treatment of renal cancer

RENCAREX[®] - first therapy in adjuvant setting for clear cell renal cell cancer

RENCAREX[®]: First therapy for adjuvant treatment of clear cell Renal Cell Carcinoma (ccRCC)

- **Monoclonal antibody for therapeutic use**
 - INN: girentuximab
 - Specifically binds to the antigen CA IX on tumour cells
 - Validated mechanism of action (ADCC*)
- **High unmet medical need**
 - Targets micro-metastases to delay onset of metastatic disease
- **No drug approved by FDA / EMA in non-metastatic ccRCC**
- **Marketing and co-development deal with Esteve for Southern Europe (2004)**
- **Peak sales potential of ~ \$500m in ccRCC only**
- **Market expansion through other indications possible**



* Antibody Dependant Cellular Cytotoxicity

RENCAREX[®]: Data of interim analysis for efficacy expected 2011

→ Phase II studies confirm biological activity

→ Increased survival of RCC patients with late stage metastatic disease

→ Phase III trial: 864 renal cancer patients enrolled

→ Non-metastatic RCC patients post nephrectomy (adjuvant setting)

→ Double-blind, placebo-controlled study in 142 sites in the Americas and Europe

→ Interim analysis of Phase III trial commenced in Q1 2011


→ Primary Endpoints: Disease free survival (DFS), determined by CT scan, and overall survival (OS)

→ IDMC recommendation based on interim data expected H2 2011

→ Could be basis for EMA filing

- **Commercialization rights to marketed drug provides the opportunity for WILEX to consider the creation of an own highly-specialized European sales & marketing organization**

- **Sales & marketing strategy for RENCAREX®**
 - USA: Prometheus
 - Southern Europe: Esteve
 - Rest of Europe: WILEX and sales partners
 - Rest of World: Enter into alliance with distributors and sales partners



Forward looking statements

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of WILEX AG. This material may not be distributed within countries where it may violate applicable law.

WILEX AG

Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-0
Fax: +49 (0)89-41 31 38-99
Website: www.wilex.com

Corporate Communications

Katja Arnold
Tel.: +49 (0)89-41 31 38-126
E-Mail: investors@wilex.com

ISIN: DE0006614720
Symbol: WL6
Reuters: WL6G.DE
Bloomberg:
WL6G.GR